A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

277

Participants

Timeline

Start Date

February 22, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Hot Flashes
Interventions
DRUG

Fezolinetant

oral

DRUG

Placebo

oral

Trial Locations (24)

Unknown

Daido Clinic, Nagoya

Juno Vesta Clinic hatta, Matsudo-shi

Mori Ladies Clinic, Fukuoka

Kotoni Ladies Clinic, Sapporo

M's Ladies Clinic, Sapporo

NISHIKAWA Women's Health Clinic, Sapporo

Motomachi Ladies Clinic, Yokohama

Women's Clinic LUNA Yokohama Motomachi, Yokohama

Chieko Yukika Lady's Clinic, Sendai

GyNet Medical Corporation Minamimorimachi Ladies' Clinic, Osaka

Ninomiya Ladies Clinic, Osaka

Rikako Ladies Clinic, Osaka

Tennoji Chihiro Women's Clinic, Osaka

Shimizu Ladies Clinic, Sakai-shi

jMOG Medical Corporation Tanabe Ladies' Clinic, Takatsuki-shi

Marunouchi no Mori Ladies Clinic, Chiyoda-ku

Ginza Yoshida Medical Clinic, Chuo-ku

Medical Corporation Asbo Tokyo Asbo Clinic, Chuo-ku

Medical Corp.SEIKOUKAI New Medical Research System Clinic, Hachioji-shi

Kichijyoji Ladies Clinic, Musashino-shi

Shimamura Memorial Hospital, Nerima-ku

Yukawa Women'S Clinic, Nishi-Tokyo-shi

Shimodaira Ladies Clinic, Suginami-ku

Medical Corporation Associa Tamacenter Ladies Clinic, Tama-Shi

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY

NCT06206421 - A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause | Biotech Hunter | Biotech Hunter